

# Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

#### SANTA CRUZ BIOTECHNOLOGY, INC.

## ZO-3 siRNA (h) sc-43538



#### BACKGROUND

Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Many of the tight junction-associated proteins are members of the membrane-associated guanylate kinase (MAGUK) family and include occludin, Z0-1, Z0-2 and Z0-3. These proteins are thought to have both structural and signaling roles, and are characteristically defined by three protein-protein interaction modules: the PDZ domain, the SH3 domain and the guanylate kinase (GuK) domain. Z0-1 forms complexes with either Z0-2 or Z0-3. In addition, these proteins can also associate with claudin, occludin and F-actin, at tight junction stands, where they provide a linkage between the actin cytoskeleton and the tight junction. Z0-1 expression is significantly reduced in many breast cancer lines. Z0-2 and Z0-3, are ubiquitously expressed within epithelial tight junctions, and unlike Z0-1, which is also expressed at cell junctions of cardiac myocytes, Z0-2 is not expressed in nonepithelial tissue.

#### REFERENCES

- Furuse, M., et al. 1994. Direct association of occludin with Z0-1 and its possible involvement in the localization of occludin at tight junctions. J. Cell Biol. 127: 1617-1626.
- 2. Anderson, J.M. 1996. Cell signalling: MAGUK magic. Curr. Biol. 6: 382-384.
- Haskins, J., et al. 1998. ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin. J. Cell Biol. 141: 199-208.
- Hoover, K.B., et al. 1998. Loss of the tight junction MAGUK Z0-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am. J. Pathol. 153: 1767-1773.
- Wittchen, E.S., et al. 1999. Protein interactions at the tight junction. Actin has multiple binding partners, and Z0-1 forms independent complexes with Z0-2 and Z0-3. J. Biol. Chem. 274: 35179-35185.
- Itoh, M., et al. 1999. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J. Cell Biol. 147: 1351-1363.

#### CHROMOSOMAL LOCATION

Genetic locus: TJP3 (human) mapping to 19p13.3.

#### PRODUCT

ZO-3 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see ZO-3 shRNA Plasmid (h): sc-43538-SH and ZO-3 shRNA (h) Lentiviral Particles: sc-43538-V as alternate gene silencing products.

For independent verification of ZO-3 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-43538A, sc-43538B and sc-43538C.

#### STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

#### **APPLICATIONS**

ZO-3 siRNA (h) is recommended for the inhibition of ZO-3 expression in human cells.

#### SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10  $\mu$ M in 66  $\mu$ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

#### GENE EXPRESSION MONITORING

ZO-3 (1E8): sc-293313 is recommended as a control antibody for monitoring of ZO-3 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

#### **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor ZO-3 gene expression knockdown using RT-PCR Primer: ZO-3 (h)-PR: sc-43538-PR (20  $\mu$ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

#### SELECT PRODUCT CITATIONS

1. Capaldo, C.T., et al. 2011. Tight function zonula occludens-3 regulates cyclin D1-dependent cell proliferation. Mol. Biol. Cell 22: 1677-1685.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.